Clinical trials
Metabolic Dysfunction-associated Fatty Liver Disease clinical trials
Below are recruiting metabolic dysfunction-associated fatty liver disease clinical trials, each written for real people, not researchers. We’re tracking 44 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07093346Recruiting
Pectin supplement for fatty liver disease
This study tests whether a pectin supplement (a fiber found in fruits) can reduce inflammation and improve liver and metabolic health in people with fatty liver disease (MASLD). You might be eligible if you have MASLD, a healthy weight range, and can avoid certain medications and foods.
Nottingham, United KingdomAges 18 years+ - NCT07083336Recruiting
Diet study for type 2 diabetes with fatty liver disease
This trial tests a specific medical nutrition therapy diet to see if it can reduce liver fat and improve blood sugar control in people with type 2 diabetes and nonalcoholic fatty liver disease. It may help you manage both conditions with a dietary approach.
Yichang, HubeiAges 18 years+ - NCT07068191Recruiting
Gepaktiv vs other drugs for fatty liver with enlarged liver
This study tests a new drug, Gepaktiv, compared to two other treatments (UDCA and ademetionine) for people with metabolic fatty liver disease who also have an enlarged liver. You may be able to join if you meet specific test results showing moderate liver fat and scarring.
Tyumen, Tyumen OblastAges 18–65 - NCT07070362Recruiting
Digital early warning system for lung injury after liver surgery
This trial tests a digital early warning system to detect acute lung injury after liver surgery. It may help doctors catch breathing problems early so they can treat them faster.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07013916Recruiting
Fructose and liver health in fatty liver disease
This study looks at how a sugar called fructose affects inflammation and metabolism in people with a type of fatty liver disease called MASH. It aims to find out if fructose plays a role in making the disease worse.
LondonAges 45–65 - NCT06953830Enrolling by invitation
Measuring spleen stiffness in veterans with fatty liver disease
This study tests a new way to measure spleen stiffness in veterans with metabolic-dysfunction fatty liver disease. It may help doctors better understand and monitor this condition without invasive procedures.
Columbia, South CarolinaAges 18 years+ - NCT06944353Enrolling by invitation
Fatty liver risk screening in the emergency department
This study looks at fatty liver findings on emergency department scans. If you have fatty liver and were sent home from the ED, the study may help connect you to follow-up care and avoid future liver problems.
Chicago, IllinoisAges 18 years+ - NCT06937749RecruitingPhase 2
Study of IBI362 for liver scarring from MASH
This trial tests an investigational drug called IBI362 for people with MASH, a type of fatty liver disease that has caused liver scarring (stage F2 or F3). The study aims to see if the drug can improve the liver's health.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06920043RecruitingPhase 2
Study of a new drug for cirrhosis from fatty liver disease
This trial tests a new medication (efimosfermin alfa) for people with cirrhosis (liver scarring) caused by MASH, a type of fatty liver disease. It aims to see if the drug can help improve liver health.
Chandler, ArizonaAges 18–75 - NCT06836609RecruitingPhase 1/Phase 2
Study of a new drug for fatty liver disease (MASLD/MASH)
This study tests a new drug called ALN-CIDEB for people with fatty liver disease (MASLD or MASH). The goal is to see if it can reduce liver fat and improve liver health. You may qualify if you have a higher BMI and evidence of liver fat on imaging tests.
Chandler, ArizonaAges 18–65 - NCT06661655Recruiting
Testing a new ultrasound for liver fat in MASLD patients
This study tests a new ultrasound device that uses sound waves to measure fat in the liver without needles or surgery. It is for people with a type of fatty liver disease called MASLD or MASH, who are already getting an MRI to check their liver.
AngersAges 18–80 - NCT06588699RecruitingPhase 2
Digoxin for NASH liver disease study
This trial tests if the heart medication digoxin can help people with NASH (fatty liver disease with inflammation), who have moderate liver scarring. You will receive digoxin or a placebo for 24 weeks and have a liver biopsy before and after treatment to see if the medication reduces liver damage.
New Haven, ConnecticutAges 18–75 - NCT06374875RecruitingPhase 4
Does metabolic surgery reduce liver scarring?
This study tests if weight loss surgery can improve liver fibrosis (scarring) in people with obesity and advanced liver disease. It may help those considering surgery to know if their liver health can get better.
Phoenix, ArizonaAges 18–75 - NCT06138821Recruiting
Endoscopic sleeve gastroplasty for obesity and MASH
This study tests if a procedure called endoscopic sleeve gastroplasty helps people with obesity and a liver condition called MASH lose weight and improve their liver health. It might be an option if you have both obesity and MASH and haven't had weight-loss surgery before.
Boston, MassachusettsAges 18 years+ - NCT05945537RecruitingPhase 1
Testing INI-822 in healthy people and those with MASH
This study tests a new oral medication (INI-822) to see if it’s safe and how the body handles it in healthy volunteers and in people with MASH. MASH is a type of fatty liver disease with inflammation and possible scarring. If you have MASH, the study also checks if the drug can improve markers of liver health. You will need to come to the study site for visits and follow strict guidelines about birth control, alcohol, and other medicines.
Camperdown, New South WalesAges 18–70 - NCT04873258Recruiting
Test a non-invasive tool to screen for fat-related liver disease
This study looks at a new non-invasive screening method to predict metabolic dysfunction–associated steatotic liver disease (MASLD), a condition where fat builds up in the liver. The goal is to help identify people who may be at risk without needing invasive tests.
London, LondonAges 18–80 - NCT06215716RecruitingPhase 3
Efruxifermin for NASH/MASH with liver scarring
This study tests a new medicine, efruxifermin, for people with NASH/MASH (fatty liver disease) and moderate liver scarring. It aims to see if the drug can help improve the liver's condition.
Birmingham, AlabamaAges 18–80 - NCT07403604RecruitingPhase 1
Lowering Insulin to Reduce Fat Buildup in the Liver
This study tests if lowering insulin levels can reduce fat buildup in the liver for people with a fatty liver condition called MASLD. It's looking for adults who are overweight and have early signs of insulin resistance but not diabetes.
New York, New YorkAges 18–65 - NCT06453915RecruitingEarly Phase 1
Brain PET scan for inflammation in fatty liver disease
This study uses a special PET scan to look for inflammation in the brain related to fatty liver disease. It may help researchers understand how liver health affects brain function.
Sacramento, CaliforniaAges 18 years+ - NCT07820644Recruiting
Liver cancer risk prediction in chronic liver disease
This study aims to predict the risk of developing liver cancer in people with chronic liver conditions such as hepatitis B or C, cirrhosis, or fatty liver disease. By participating, you may help researchers improve early detection and prevention strategies for liver cancer.
Shenzhen, GuangdongAges 18–75
Hear when a new Metabolic Dysfunction-associated Fatty Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metabolic dysfunction-associated fatty liver disease?
- Yes. Clin2 currently lists 44 recruiting metabolic dysfunction-associated fatty liver disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metabolic dysfunction-associated fatty liver disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metabolic dysfunction-associated fatty liver disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)
- Metabolic Dysfunction-Associated Steatotic Liver Disease
- Metabolic Associated Fatty Liver Disease
- Metabolic Dysfunction-Associated Liver Disease
- MASH - Metabolic Dysfunction-Associated Steatohepatitis
- Metabolic Associated Steatotic Liver Disease
- Non-Alcoholic Fatty Liver Disease
- Fatty Liver
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.